摘要
目的探讨NT-proBNP联合cTnⅠ在心衰检测中的应用价值。方法回顾性分析2017年11月—2018年11月该院95例心力衰竭患者的临床资料,并将其作为研究组。回顾性分析该院103例无心力衰竭心血管疾病患者的临床资料,将其作为对照组。两组均行NT-proBNP与cTnⅠ检测。观察比较两组血清NT-proBNP与cTnⅠ水平,以及研究组心力衰竭NT-proBNP、cTnⅠ与NT-proBNP联合cTnⅠ检测的结果。结果研究组血清NT-proBNP(985.5±205.6)ng/L、cTnⅠ(5.5±2.6)μg/L,均高于对照组血清(112.5±45.6)ng/L,(0.5±0.2)μg/L(t=12.523,10.852,P<0.01)。研究组心力衰竭患者采用NT-proBNP联合cTnⅠ检测的特异度90.3%与符合率89.4%,高于单纯cTnⅠ79.6%、70.7%(χ^2=4.595, 21.647,P<0.05或P<0.01)与NT-proBNP69.9%、62.6%(χ^2=13.428,38.900,P<0.01)。结论 NT-proBNP联合cTnⅠ的心力衰竭检测中具有显著的临床应用价值,值得推广。
Objective To explore the application value of NT-proBNP combined with cTnI in heart failure detection. Methods The clinical data of 95 patients with heart failure in our hospital from November 2017 to November 2018 were retrospectively analyzed and used as the study group. The clinical data of 103 patients with cardiovascular disease without heart failure in our hospital were retrospectively analyzed and used as a control group. NT-proBNP and cTnⅠ were detected in both groups. The levels of serum NT-proBNP and cTnⅠ were compared between the two groups, and the results of NT-proBNP, cTnⅠ and NT-proBNP combined with cTnⅠ in the study group. Results Serum NT-proBNP (985.5±205.6)ng/L and cTnⅠ (5.5±2.6)μg/L were higher in the study group than in the control group (112.5±45.6)ng/L,(0.5±0.2)μg/L(t=12.523, 10.852, P<0.01). In the study group, the specificity of NT-proBNP combined with cTnI was 90.3% and the coincidence rate was 89.4%, which was higher than that of cTnI 79.6%, 70.7%(χ^2=4.595, 21.647, P<0.05 or P<0.01) and NT-proBNP 69.9%, 62.6%(χ^2=13.428, 38.900, P<0.01). Conclusion NT-proBNP combined with cTnI has significant clinical value in the detection of heart failure and is worthy of promotion.
作者
康翠屏
薛秀儒
王标
KANG Cui-ping;XUE Xiu-ru;WANG Biao(Department of Clinical Laboratory,Second People's Hospital of Chengyang District,Qingdao,Shandong Province,266112 China)
出处
《中外医疗》
2019年第14期14-16,共3页
China & Foreign Medical Treatment
